Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 7, 2005, Pages 3877-3885

  Kananen, Kristiina ^a   Volin, Liisa ^a   Laitinen, Kalevi ^a   Alfthan, Henrik ^a   Ruutu, Tapani ^a   Välimäki, Matti J ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CARBONATE; CYCLOSPORIN A; ESTROGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PAMIDRONIC ACID; TESTOSTERONE; THALIDOMIDE; VITAMIN D;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; FEMUR NECK; FINLAND; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX RATIO;

ADULT; AGED; BONE DENSITY; BONE REMODELING; CALCIUM CARBONATE; DIPHOSPHONATES; FEMALE; GONADAL STEROID HORMONES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; TRANSPLANTATION, HOMOLOGOUS; VITAMIN D;

EID: 23044471691     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2004-2161     Document Type: Article

References (52)

1. Katz IA, Epstsein S 1992 Perspectives. Posttransplantation bone disease. J Bone Miner Res 7:123-126
2. Cohen A, Shane E 2003 Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int 14:617-630
3. Välimäki MJ, Kinnunen K, Volin L, Tähtelä R, Löyttyniemi E, Laitinen K, Mäkelä P, Keto P, Ruutu T 1999Aprospective study of bone loss and turnover after allogeneic bone marrow transplantation; effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant 23:355-361
4. Ebeling PR, Thomas DM, Ebras B, Hopper JL, Szer J, Grigg AP 1999 Mechanism of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. J Bone Miner Res 14:342-350
5. Schulte C, Beelen DW, Schaefer UW, Mann K 2000 Bone loss in long-term survivors after transplantation of hematopoietic stem cells: a prospective study. Osteoporos Int 11:344-353
6. Massenkeil G, Fiene C, Rosen O, Michael R, Reisinger W, Arnold R 2001 Loss of bone mass and vitamin D deficiency after hematopoietic stem cell transplantation: standard prophylactic measures fail to prevent osteoporosis. Leukemia 15:1701-1705
7. Lee WY, Cho SW, Oh ES, Oh KW, Lee JM, Yoon KH, Kang MI, Cha BY, Lee KW, Son HY, Kang SK, Kim CC 2002 The effects of stem cell transplantation on the osteoblastic differentiation of human bone stromal cells. J Clin Endocrinol Metab 87:329-335
8. Schulte CMS, Beelen DW 2004 Bone loss following hematopoietic stem cell transplantation: a long-term follow-up. Blood 103:3635-3643
9. Kauppila M, Irjala K, Koskinen P, Pulkki K, Sonninen P, Viikari J, Remes K 1999 Bone mineral density after allogeneic bone marrow transplantation. Bone Marrow Transplant 24:885-889
10. Gandhi MK, Lekamwasam S, Inman I, Kaptoge S, Sizer L, Love S, Bearcroft PW, Milligan TP, Price CP, Marcus RE, Copston JE 2003 Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: long-term follow-up of prospective study. Br J Haematol 121:462-468
11. Epstein S 1996 Post-transplantation osteoporosis; the role of immunosuppressive agents and the skeleton. J Bone Miner Res 11:1-7
12. Kananen K, Volin L, Tähtelä R, Laitinen K, Ruutu T, Välimäki MJ 2002 Recovery of bone mass and normalization of bone turnover in long-term survivors of allogeneic bone marrow transplantation. Bone Marrow Transplant 29:33-39
13. Canalis E, Delany AM 2002 Mechanism of glucocorticoid action in bone. Ann NY Acad Sci 966:73-81
14. Epstein S, Dissanayake IR, Goodman GR, Bowman AR, Zhou H, Ma Y, Jee WS 2001 Effect of the interaction of parathyroid hormone and cyclosporine A on bone mineral metabolism in the rat. Calcif Tissue Int 68: 240-247
15. Lee WY, Kang MI, Oh ES, Oh KW, Han JH, Cha BY, Lee KW, Son HY, Kang SK, Kim CC 2002 The role of cytokines in the changes in bone turnover following bone marrow transplantation. Osteoporos Int 13:62-68
16. Banfi A, Podesta M, Fazzuoli L, Venturini M, Santini G, Cancedda R, Quarto R 2001 High-dose chemotherapy shows a dose-dependent toxicity to stem cell osteoprogenitors - a mechanism for post-bone marrow transplantation osteopenia. Cancer 92:2419-2428
17. Hovi L, Rajantie M, Perkkiö M, Sainio K, Sipilä, Siimes MA 1990 Growth failure and growth hormone deficiency in children after stem cell transplantation for leukaemia. Bone Marrow Transplant 5:183-186
18. Talvensaari KK, Lanning M, Pääkkö E, Tapanainen P, Knip M 1994 Pituitary size assessed with magnetic resonance imaging as a measure of growth hormone secretion in long term survivors of childhood cancer. J Clin Endocrinol Metab 79:1122-1127
19. Sullivan KM 2004 Graft-vs.-host disease. In: Blume KG, Forman SJ, Appelbaum F, eds. Thomas' hematopoietic cell transplantation. Malden, MA: Blackwell Publishers; 635-664
20. Castelo-Branco C, Rovira M, Pons F, Durán M, Sierra J, Vives A, Balasch J, Fortuny A, Vanrell J 1996 The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas 23:307-312
21. Shane E, Addesso V, Namerow PB, McMahon DJ, Lo S-H, Staron RB, Zucker M, Pardi S, Maybaum S, Mancini D 2004 Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 350:767-776
22. Shane E, Rodino MA, Mcmahon DJ, Addesso V, Staron RB, Seibel MJ, Mancini D, Michler RE, Lo SH 1998 Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. J Heart Lung Transplant 17:1089-1096
23. Reeves HL, Francis RM, Manas DM, Hudson M, Day CP 1998 Intravenous bisphosphonate prevents osteoporotic vertebral collapse in patients after liver transplantation. Liver Transplant Surg 4:404-409
24. Giannini S, D'Angelo A, Carraro G, Nobile M, Rigotti P, Bonfante L, Marchini F, Zaninotto M, Dalle Carbonare L, Sartori L, Crepaldi G 2001 Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 16:2111-2117
25. Grotz W, Nagel C, Poeschel D, Nobile M, Rigotti P, Bonfante L, Marchini F, Zaninotto M, Carbonare LD, Santori L, Crepaldi G 2001 Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 12:1530-1537
26. Henderson K, Eisman J, Keogh A, Macdonald P, Glanville A, Spratt P, Samrook P 2001 Protective effect of short-term calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation. J Bone Miner Res 16:565-571
27. Buchs N, Helg C, Collao C, Chapuis B, Slosman D, Bonjour JP, Rizzoli R 2001 Allogeneic bone marrow transplantation is associated with a preferential femoral neck bone loss. Osteoporos Int 12:880-886
28. Tauchmanova L, Selleri C, Esposito M, Di Somma C, Orio F Jr., Bifulco G, Palomba S, Lombardi G, Rotoli B, Colao A 2003 Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. Osteoporos Int 14:1013-1019
29. Tauchmanova L, Ricci P, Serio B, Lombardi G, Colao A, Rotoli B, Selleri C 2005 Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. J Clin Endocrinol Metab 90:627-634
30. Duncombe A 1997 ABC of clinical haematology. Stem cell and bone marrow transplantation. Br Med J 314:1179-1182
31. Ruutu T, Volin L, Parkkali T, Juvonen E, Elonen E 2000 Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood 96:2391-2398
32. Cauley JA, Robbins J, Chen Z 2003 Effects of estrogen plus progestin on risk of fracture and bone mineral density. JAMA 290:1729-1738
33. Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002 288:605-613
34. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL 2000 Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85:2670-2677
35. Haas M, Leko-Mohr Z, Roschger P, Kletzmayer J, Schwarz C, Mitterbauer C, Steininger R, Grampp S, Klaushoffer K, Delling G, Oberbauer R 2003 Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 63:1130-1136
36. Tauchmanova L, Serio B, del Puente A, Risitano AM, Esposito A, de Rosa G, Lombardi G, Colao A, Rotoli B, Selleri C 2002 Long-lasting bone damage detected by dual-energy X-ray absorptiometry, phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation. J Clin Endocrinol Metab 87:5058-5065
37. Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P, Tellis V, Greenstein S, Schechner R, Figueroa K, McDonough P, Wang G, Malluche H 2003 Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 14:2669-2676
38. Hassager C, Risteli J, Risteli L, Jensen SB, Christiansen C 1992 Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women. J Bone Miner Res 7:1307-1311
39. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541
40. Adachi JD, Bensen WG, Brown J, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste.-Marie L-G, Tenenhouse A, Chines AA 1997 Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382-387
41. Pols HAP, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B 1999 Multinational, placebo-controlled, randomised trial of the effects of the alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT-study. Osteoporos Int 9:461-468
42. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP 2000 Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15:1006-1013
43. Atley LM, Mort JS, Lalumiere M, Eyre DR 2000 Proteolysis of human bone collagen by cathepsin K: characterization of the cleavage sites generating the cross-linked N-telopeptide neoepitope. Bone 26:241-247
44. Sassi M-L, Eriksen H, Risteli L Niemi S, Mansell J, Gowen M, Risteli L 2000 Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 26:367-373
45. Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT, Delaissé JM 2003 The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18:859-867
46. Garnero P, Shih WJ, Gineyts E 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700
47. Christgau S, Bitsch-Jensen O, Hanover Bjarnason N, Gamwell Henriksen E, Qvist P, Alexandersen P, Bang Henriksen D 2000 Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 26:505-511
48. Halleen JM, Alatalo SL, Janckila AJ, Woitge HW, Seibel MJ, Väänänen HK 2001 Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 47:597-600
49. Janckila AJ, Takahashi K, Sun SZ, Yam LT 2001 Tartrate-resistant acid phosphatase isoform 5b as serum marker of osteoclastic activity. Clin Chem 47:74-80
50. Chambers TJ, Darby JA, Fuller K 1985 Mammalian collagenase predisposes bone surfaces to osteoclastic resorption. Cell Tissue Res 241:671-675
51. Blavier L, Delaisse JM 1995 Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones. J Cell Sci 108:3649-3659
52. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM 1993 Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 341:72-75